<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01217099</url>
  </required_header>
  <id_info>
    <org_study_id>ChiCTR-TRC2</org_study_id>
    <nct_id>NCT01217099</nct_id>
  </id_info>
  <brief_title>Methylprednisolone Pulse Macrolide Therapy for Refractory Mycoplasma Pneumoniae Pneumonia in Children</brief_title>
  <acronym>MPP</acronym>
  <official_title>A Prospective, Open-label Trial of Methylprednisolone Pulse Macrolide Therapy for Refractory Mycoplasma Pneumoniae Pneumonia in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chongqing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chongqing Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is planned to investigate whether small doses of methylprednisolone&#xD;
      pulse macrolide therapy can relieve symptoms,chest X-rays faster than macrolide alone therapy&#xD;
      for refractory mycoplasma pneumoniae pneumonia(MPP) .&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Corticosteroid has been used in adulthood refractory MPP with satisfactory efficacy. But&#xD;
      there were few studies about the use of corticosteroid in children with refractory MPP. Lee&#xD;
      KY et al indicated oral prednisolone of 1 mg/kg/ day for 1 week be useful for children with&#xD;
      severe MPP. Akihiro T et al demonstrated that intravenously administered methylprednisolone&#xD;
      at a dose of 30 mg/kg once daily for 3 consecutive days had an efficacious treatment for&#xD;
      children with refractory MPP.But the methods of corticosteroid use, such as the dosage,&#xD;
      administration route, duration of treatment have not been well understood. So in this study,&#xD;
      we planned to investigate whether small doses of methylprednisolone pulse macrolide therapy&#xD;
      can relieve symptoms,chest X-rays faster than macrolide alone therapy for refractory&#xD;
      mycoplasma pneumoniae pneumonia in a prospective, open-label fashion.&#xD;
&#xD;
      PMID: 11096025 PMID: 18033831 PMID: 10434547 PMID: 16437541 PMID: 18656264&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    terminated&#xD;
  </why_stopped>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>efficacy of methylprednisolone pulse macrolide therapy for children with refractory MPP.</measure>
    <time_frame>3-year</time_frame>
    <description>compare the temperature , infiltration absorption,atelectasis resolution, pleural effusion disappearance,serum levels of ferritin and LDH between methylprednisolone pulse macrolide therapy group and macrolide therapy group .</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>safety of methylprednisolone pulse macrolide therapy for children with refractory MPP.</measure>
    <time_frame>3-year</time_frame>
    <description>observe the further complications of infection between methylprednisolone pulse macrolide therapy group and macrolide therapy group .</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Refractory Mycoplasma Pneumoniae Pneumonia</condition>
  <arm_group>
    <arm_group_label>methylprednisolone</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>methylprednisolone pulse azithromycin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>azithromycin</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>azithromycin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methylprednisolone</intervention_name>
    <description>treatment patients were iv methylprednisolone pulse azithromycin for 5 days.</description>
    <arm_group_label>methylprednisolone</arm_group_label>
    <other_name>treatment group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>azithromycin</intervention_name>
    <description>control patients were iv azithromycin for 5 days.</description>
    <arm_group_label>azithromycin</arm_group_label>
    <other_name>control group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  mycoplasma pneumoniae pneumonia&#xD;
&#xD;
          -  prolonged fever and deterioration of radiological findings despite macrolides&#xD;
             treatment for 7 days or more.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  chronic cardiac and pulmonary disease&#xD;
&#xD;
          -  immunodeficiency&#xD;
&#xD;
          -  requiring mechanical ventilation&#xD;
&#xD;
          -  with other pathogens detected during pneumonia.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>zhengxiu luo, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chongqing Medical University</affiliation>
  </overall_official>
  <link>
    <url>http://www.clinicaltrials.gov</url>
    <description>Related Info</description>
  </link>
  <verification_date>May 2007</verification_date>
  <study_first_submitted>October 6, 2010</study_first_submitted>
  <study_first_submitted_qc>October 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2010</study_first_posted>
  <last_update_submitted>October 7, 2010</last_update_submitted>
  <last_update_submitted_qc>October 7, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 8, 2010</last_update_posted>
  <responsible_party>
    <name_title>zhengxiu luo</name_title>
    <organization>Children's Hospital of Chongqing Medical University</organization>
  </responsible_party>
  <keyword>refractory mycoplasma pneumoniae pneumonia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Pleuropneumonia</mesh_term>
    <mesh_term>Mycoplasma Infections</mesh_term>
    <mesh_term>Pneumonia, Mycoplasma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

